{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T02:39:14Z","timestamp":1782441554613,"version":"3.54.5"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005851","name":"Shahid Beheshti University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ejphar.2024.176882","type":"journal-article","created":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T01:23:14Z","timestamp":1723252994000},"page":"176882","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The role of interferon beta in neurological diseases and its potential therapeutic relevance"],"prefix":"10.1016","volume":"981","author":[{"given":"Mohsen","family":"Farhangian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Forouzan","family":"Azarafrouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3880-4325","authenticated-orcid":false,"given":"Neda","family":"Valian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7777-5435","authenticated-orcid":false,"given":"Leila","family":"Dargahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2024.176882_bib1","first-page":"19386","article-title":"STING manifests self DNA-dependent inflammatory disease","volume":"109","author":"Ahn","year":"2012"},{"key":"10.1016\/j.ejphar.2024.176882_bib2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00044011-199714010-00005","article-title":"Pharmacokinetics and pharmacodynamics of interferon Beta-la (IFN\u03b2-1a) in healthy volunteers after intravenous, subcutaneous or intramuscular administration","volume":"14","author":"Alam","year":"1997","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.ejphar.2024.176882_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00778","article-title":"Sources of type I interferons in infectious immunity: plasmacytoid dendritic cells not always in the driver's seat","volume":"10","author":"Ali","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176882_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2019.00282","article-title":"Traumatic spinal cord injury: an overview of pathophysiology, models and acute injury mechanisms","volume":"10","author":"Alizadeh","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejphar.2024.176882_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.573560","article-title":"RNA sequencing of human peripheral blood cells indicates upregulation of immune-related genes in huntington's disease","volume":"11","author":"Andrade-Navarro","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.ejphar.2024.176882_bib6","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pep.2003.11.004","article-title":"Expression, purification, and characterization of rat interferon-\u03b2, and preparation of an N-terminally PEGylated form with improved pharmacokinetic parameters","volume":"34","author":"Arduini","year":"2004","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.ejphar.2024.176882_bib7","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.1038\/onc.2017.205","article-title":"Human SLFN5 is a transcriptional co-repressor of STAT1-mediated interferon responses and promotes the malignant phenotype in glioblastoma","volume":"36","author":"Arslan","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ejphar.2024.176882_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.npep.2022.102262","article-title":"Interferon beta attenuates recognition memory impairment and improves brain glucose uptake in a rat model of Alzheimer's disease: involvement of mitochondrial biogenesis and PI3K pathway","volume":"95","author":"Azarafrouz","year":"2022","journal-title":"Neuropeptides"},{"key":"10.1016\/j.ejphar.2024.176882_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111398","article-title":"Nod-like receptors: critical intracellular sensors for host protection and cell death in microbial and parasitic infections","volume":"22","author":"Babamale","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.176882_bib10","doi-asserted-by":"crossref","first-page":"12826","DOI":"10.1523\/JNEUROSCI.4937-05.2006","article-title":"Toll-like receptor 2 signaling in response to brain injury: an innate bridge to neuroinflammation","volume":"26","author":"Babcock","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176882_bib11","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1021\/bc050322y","article-title":"Structure\u2212 function engineering of interferon-\u03b2-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation","volume":"17","author":"Basu","year":"2006","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.ejphar.2024.176882_bib12","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.3389\/fimmu.2018.02129","article-title":"Interferon-\u03b1 up-regulates the expression of PD-L1 molecules on immune cells through STAT3 and p38 signaling","volume":"9","author":"Bazhin","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176882_bib13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1212\/WNL.54.2.469","article-title":"A randomized controlled trial of recombinant interferon beta-1a in ALS","volume":"54","author":"Beghi","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2024.176882_bib14","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/glia.23154","article-title":"Type I interferon pathway in CNS homeostasis and neurological disorders","volume":"65","author":"Blank","year":"2017","journal-title":"Glia"},{"key":"10.1016\/j.ejphar.2024.176882_bib15","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2422","article-title":"Interferons at age 50: past, current and future impact on biomedicine","volume":"6","author":"Borden","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2024.176882_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01586","article-title":"Comparative structure and function analysis of the RIG-I-like receptors: RIG-I and MDA5","volume":"10","author":"Brisse","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176882_bib17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1365-2567.2006.02485.x","article-title":"Toll\u2010like receptor interactions: tolerance of MyD88\u2010dependent cytokines but enhancement of MyD88\u2010independent interferon\u2010\u03b2 production","volume":"120","author":"Broad","year":"2007","journal-title":"Immunology"},{"key":"10.1016\/j.ejphar.2024.176882_bib18","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/jnr.22767","article-title":"Toll\u2010like receptors 2 and 3 agonists differentially affect oligodendrocyte survival, differentiation, and myelin membrane formation","volume":"90","author":"Bsibsi","year":"2012","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ejphar.2024.176882_bib19","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1089\/10799900050163226","article-title":"Pharmacokinetics and pharmacodynamics of IFN-\u03b21a in healthy volunteers","volume":"20","author":"Buchwalder","year":"2000","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.ejphar.2024.176882_bib20","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.3469","article-title":"Identifying and verifying Huntington's disease subtypes: clinical features, neuroimaging, and cytokine changes","volume":"14","author":"Cao","year":"2024","journal-title":"Brain and Behavior"},{"key":"10.1016\/j.ejphar.2024.176882_bib21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cytogfr.2014.10.011","article-title":"Type I IFN family members: similarity, differences and interaction","volume":"26","author":"Capobianchi","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ejphar.2024.176882_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2019.109661","article-title":"Interferon beta ameliorates cognitive dysfunction in a rat model of Alzheimer's disease: modulation of hippocampal neurogenesis and apoptosis as underlying mechanism","volume":"94","author":"Chavoshinezhad","year":"2019","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatr."},{"key":"10.1016\/j.ejphar.2024.176882_bib23","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.brainresbull.2019.06.015","article-title":"Intranasal interferon beta improves memory and modulates inflammatory responses in a mutant APP-overexpressing rat model of Alzheimer's disease","volume":"150","author":"Chavoshinezhad","year":"2019","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ejphar.2024.176882_bib24","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1093\/brain\/awt061","article-title":"Interferon beta induces clearance of mutant ataxin 7 and improves locomotion in SCA7 knock-in mice","volume":"136","author":"Chort","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2024.176882_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12017-009-8104-z","article-title":"An overview of APP processing enzymes and products","volume":"12","author":"Chow","year":"2010","journal-title":"NeuroMolecular Med."},{"key":"10.1016\/j.ejphar.2024.176882_bib26","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s11064-019-02800-w","article-title":"Spinal cord injury: animal models, imaging tools and the treatment strategies","volume":"45","author":"Cizkova","year":"2020","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ejphar.2024.176882_bib27","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1042\/BJ20100323","article-title":"Mechanisms and functions of p38 MAPK signalling","volume":"429","author":"Cuadrado","year":"2010","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejphar.2024.176882_bib28","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1046\/j.1460-9568.2003.02662.x","article-title":"Synaptic changes characterize early behavioural signs in the ME7 model of murine prion disease","volume":"17","author":"Cunningham","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176882_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2005.08.029","article-title":"Interferon and the central nervous system","volume":"523","author":"Dafny","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176882_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005096","article-title":"Knocking on closed doors: host interferons dynamically regulate blood-brain barrier function during viral infections of the central nervous system","volume":"11","author":"Daniels","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ejphar.2024.176882_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023135","article-title":"MyD88 and STING signaling pathways are required for IRF3-mediated IFN-\u03b2 induction in response to Brucella abortus infection","volume":"6","author":"de Almeida","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2024.176882_bib32","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/19336896.2021.1991771","article-title":"The role of microglia in prion diseases and possible therapeutic targets: a literature review","volume":"15","author":"de Melo","year":"2021","journal-title":"Prion"},{"key":"10.1016\/j.ejphar.2024.176882_bib33","doi-asserted-by":"crossref","first-page":"7554","DOI":"10.1074\/jbc.M116.773788","article-title":"A hot spot on interferon \u03b1\/\u03b2 receptor subunit 1 (IFNAR1) underpins its interaction with interferon-\u03b2 and dictates signaling","volume":"292","author":"de Weerd","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2024.176882_bib34","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/icb.2012.9","article-title":"The interferons and their receptors\u2014distribution and regulation","volume":"90","author":"De Weerd","year":"2012","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.ejphar.2024.176882_bib35","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/ni.2667","article-title":"Structural basis of a unique interferon-\u03b2 signaling axis mediated via the receptor IFNAR1","volume":"14","author":"De Weerd","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejphar.2024.176882_bib36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer's disease","volume":"14","author":"DeTure","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.ejphar.2024.176882_bib37","first-page":"193","article-title":"Bio equivalence of Two Subcutaneous Pharmaceutical Products of Interferon Beta la","volume":"58","author":"Di Girolamo","year":"2008","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ejphar.2024.176882_bib38","series-title":"D09 Exploring Neurodegeneration and Inflammation Blood Biomarkers in a Cohort of Italian Patients with Huntington's Disease","author":"Di Lazzaro","year":"2022"},{"key":"10.1016\/j.ejphar.2024.176882_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/1759091416670492","article-title":"Intranasal administration of interferon beta attenuates neuronal apoptosis via the JAK1\/STAT3\/BCL-2 pathway in a rat model of neonatal hypoxic-ischemic encephalopathy","volume":"8","author":"Dixon","year":"2016","journal-title":"ASN neuro"},{"key":"10.1016\/j.ejphar.2024.176882_bib40","doi-asserted-by":"crossref","first-page":"a028035","DOI":"10.1101\/cshperspect.a028035","article-title":"Pathology of neurodegenerative diseases","volume":"9","author":"Dugger","year":"2017","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.ejphar.2024.176882_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00920","article-title":"Heat-shock proteins in neuroinflammation","volume":"10","author":"Dukay","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176882_bib42","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.cell.2015.08.069","article-title":"Lack of neuronal IFN-\u03b2-IFNAR causes Lewy body-and Parkinson's disease-like dementia","volume":"163","author":"Ejlerskov","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2024.176882_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2022.136968","article-title":"Intranasal interferon-beta alleviates anxiety and depressive-like behaviors by modulating microglia polarization in an Alzheimer's disease model","volume":"792","author":"Farhangian","year":"2023","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2024.176882_bib44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0404.1984.tb00801.x","article-title":"Neurotoxic and other side effects of high\u2010dose interferon in amyotrophic lateral sclerosis","volume":"70","author":"F\u00e4rkkil\u00e4","year":"1984","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.ejphar.2024.176882_bib45","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1523\/JNEUROSCI.3547-03.2004","article-title":"Reactive astrocytes protect tissue and preserve function after spinal cord injury","volume":"24","author":"Faulkner","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176882_bib46","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(22)01272-7","article-title":"Amyotrophic lateral sclerosis","volume":"400","author":"Feldman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2024.176882_bib47","article-title":"Cytokines and interferons: types and functions","volume":"13","author":"Ferreira","year":"2018","journal-title":"Autoantibodies and cytokines"},{"key":"10.1016\/j.ejphar.2024.176882_bib48","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fncel.2018.00329","article-title":"Role of microglia TLRs in neurodegeneration","volume":"12","author":"Fiebich","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176882_bib49","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.bbi.2010.04.004","article-title":"Systemic challenge with the TLR3 agonist poly I: C induces amplified IFN\u03b1\/\u03b2 and IL-1\u03b2 responses in the diseased brain and exacerbates chronic neurodegeneration","volume":"24","author":"Field","year":"2010","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.ejphar.2024.176882_bib50","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7224\/1537-2073.2018-063","article-title":"Interferons in the treatment of multiple sclerosis: a clinical efficacy, safety, and tolerability update","volume":"22","author":"Filipi","year":"2020","journal-title":"International journal of MS care"},{"key":"10.1016\/j.ejphar.2024.176882_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01015","article-title":"Interferon-\u03bbs and plasmacytoid dendritic cells: a close relationship","volume":"8","author":"Finotti","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176882_bib52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cytogfr.2007.10.006","article-title":"Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history","volume":"19","author":"Fitzgerald-Bocarsly","year":"2008","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ejphar.2024.176882_bib53","doi-asserted-by":"crossref","unstructured":"Fukata, M., Vamadevan, A.S. & Abreu, M.T. (Year) Toll-like Receptors (TLRs) and Nod-like Receptors (NLRs) in Inflammatory Disorders. Vol. 21, Seminars in immunology. Elsevier, City. p. 242-253.","DOI":"10.1016\/j.smim.2009.06.005"},{"key":"10.1016\/j.ejphar.2024.176882_bib54","doi-asserted-by":"crossref","first-page":"16269","DOI":"10.1523\/JNEUROSCI.4000-11.2011","article-title":"Spinocerebellar ataxia type 7 cerebellar disease requires the coordinated action of mutant ataxin-7 in neurons and glia, and displays non-cell-autonomous bergmann glia degeneration","volume":"31","author":"Furrer","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176882_bib55","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1471-4159.2012.07946.x","article-title":"Poly\u2010ICLC preconditioning protects the blood\u2013brain barrier against ischemic injury in vitro through type I interferon signaling","volume":"123","author":"Gesuete","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2024.176882_bib56","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/bph.12010","article-title":"IFN\u2010\u03b1 subtypes: distinct biological activities in anti\u2010viral therapy","volume":"168","author":"Gibbert","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176882_bib57","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1089\/jir.2010.0098","article-title":"Role of differential expression of interferon receptor isoforms on the response of multiple sclerosis patients to therapy with interferon beta","volume":"30","author":"Gilli","year":"2010","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.ejphar.2024.176882_bib58","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrneurol.2017.165","article-title":"Parkinson's disease\u2014the story of an eponym","volume":"14","author":"Goedert","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejphar.2024.176882_bib59","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41584-021-00606-1","article-title":"Interferon lambda in inflammation and autoimmune rheumatic diseases","volume":"17","author":"Goel","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.ejphar.2024.176882_bib60","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/01.brs.0000259841.40358.8f","article-title":"Effect of immunomodulation with human interferon-\u03b2 on early functional recovery from experimental spinal cord injury","volume":"32","author":"Gok","year":"2007","journal-title":"Spine"},{"key":"10.1016\/j.ejphar.2024.176882_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.818757","article-title":"The molecular basis of spinocerebellar ataxia type 7","volume":"16","author":"Goswami","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176882_bib62","doi-asserted-by":"crossref","first-page":"13925","DOI":"10.1074\/jbc.R116.774745","article-title":"Current prospects of type II interferon \u03b3 signaling and autoimmunity","volume":"292","author":"Green","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2024.176882_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-11-30","article-title":"A pilot study on the use of interferon beta-1a in early Alzheimer's disease subjects","volume":"11","author":"Grimaldi","year":"2014","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ejphar.2024.176882_bib64","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1517\/17425255.2015.1094055","article-title":"Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-\u03b2","volume":"11","author":"Hegen","year":"2015","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.ejphar.2024.176882_bib65","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer's disease","volume":"14","author":"Heneka","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejphar.2024.176882_bib66","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.it.2005.05.004","article-title":"Viruses know it all: new insights into IFN networks","volume":"26","author":"Hengel","year":"2005","journal-title":"Trends Immunol."},{"key":"10.1016\/j.ejphar.2024.176882_bib67","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.immuni.2006.08.009","article-title":"Type I inteferon gene induction by the interferon regulatory factor family of transcription factors","volume":"25","author":"Honda","year":"2006","journal-title":"Immunity"},{"key":"10.1016\/j.ejphar.2024.176882_bib68","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/jcph.390","article-title":"Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta\u20101a in subjects with normal or impaired renal function","volume":"55","author":"Hu","year":"2015","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2024.176882_bib69","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.3233\/JAD-221081","article-title":"The role of interferon-\u03b1 in neurodegenerative diseases: a systematic review","volume":"94","author":"Hui","year":"2023","journal-title":"J. Alzheim. Dis."},{"key":"10.1016\/j.ejphar.2024.176882_bib70","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fnagi.2020.00004","article-title":"Strategies for the treatment of Parkinson's disease: beyond dopamine","volume":"12","author":"Iarkov","year":"2020","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejphar.2024.176882_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-015-0427-0","article-title":"Endogenous IFN-\u03b2 signaling exerts anti-inflammatory actions in experimentally induced focal cerebral ischemia","volume":"12","author":"In\u00e1cio","year":"2015","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ejphar.2024.176882_bib72","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/brain\/awz016","article-title":"Type I interferon protects neurons from prions in in vivo models","volume":"142","author":"Ishibashi","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.ejphar.2024.176882_bib73","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1089\/neu.2008.0646","article-title":"Type I interferon inhibits astrocytic gliosis and promotes functional recovery after spinal cord injury by deactivation of the MEK\/ERK pathway","volume":"26","author":"Ito","year":"2009","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.ejphar.2024.176882_bib74","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.4049\/jimmunol.175.7.4320","article-title":"TLR signaling tailors innate immune responses in human microglia and astrocytes","volume":"175","author":"Jack","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2024.176882_bib75","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1083\/jcb.200511045","article-title":"PML clastosomes prevent nuclear accumulation of mutant ataxin-7 and other polyglutamine proteins","volume":"174","author":"Janer","year":"2006","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejphar.2024.176882_bib76","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-\u03b3 in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.ejphar.2024.176882_bib77","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1515\/bmc-2018-0007","article-title":"Interferon-gamma (IFN-\u03b3): exploring its implications in infectious diseases","volume":"9","author":"Kak","year":"2018","journal-title":"Biomol. Concepts"},{"key":"10.1016\/j.ejphar.2024.176882_bib78","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/glia.22375","article-title":"Oligodendroglia are limited in type I interferon induction and responsiveness in vivo","volume":"60","author":"Kapil","year":"2012","journal-title":"Glia"},{"key":"10.1016\/j.ejphar.2024.176882_bib79","doi-asserted-by":"crossref","first-page":"7723","DOI":"10.1073\/pnas.1118122109","article-title":"Regulatory effects of mTORC2 complexes in type I IFN signaling and in the generation of IFN responses","volume":"109","author":"Kaur","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejphar.2024.176882_bib80","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/jnr.20767","article-title":"Toll\u2010like receptors in central nervous system glial inflammation and homeostasis","volume":"83","author":"Kielian","year":"2006","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ejphar.2024.176882_bib81","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/11591110-000000000-00000","article-title":"The mechanism of action of interferon-\u03b2 in relapsing multiple sclerosis","volume":"25","author":"Kieseier","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejphar.2024.176882_bib82","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.expneurol.2014.01.001","article-title":"Pattern recognition receptors and central nervous system repair","volume":"258","author":"Kigerl","year":"2014","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2024.176882_bib83","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/1073858411401413","article-title":"Dopaminergic neurotransmission in the human brain: new lessons from perturbation and imaging","volume":"18","author":"Ko","year":"2012","journal-title":"Neuroscientist"},{"key":"10.1016\/j.ejphar.2024.176882_bib84","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1074\/jbc.RA118.005956","article-title":"Sirtuin 2\u2013mediated deacetylation of cyclin-dependent kinase 9 promotes STAT1 signaling in type I interferon responses","volume":"294","author":"Kosciuczuk","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2024.176882_bib85","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/ana.20161","article-title":"Interferon\u2010\u03b2 stabilizes barrier characteristics of brain endothelial cells in vitro","volume":"56","author":"Kraus","year":"2004","journal-title":"Ann. Neurol.: Official Journal of the American Neurological Association and the Child Neurology Society"},{"key":"10.1016\/j.ejphar.2024.176882_bib86","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002610","article-title":"Interferon\u2010\u03b2 modulates inflammatory response in cerebral ischemia","volume":"5","author":"Kuo","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ejphar.2024.176882_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02614","article-title":"Photodynamic modulation of type 1 interferon pathway on melanoma cells promotes dendritic cell activation","volume":"10","author":"Lamberti","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176882_bib88","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.immuni.2015.07.001","article-title":"Interferon-\u03bb: immune functions at barrier surfaces and beyond","volume":"43","author":"Lazear","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.ejphar.2024.176882_bib89","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.immuni.2019.03.025","article-title":"Shared and distinct functions of type I and type III interferons","volume":"50","author":"Lazear","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ejphar.2024.176882_bib90","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02061","article-title":"The dual nature of type I and type II interferons","volume":"9","author":"Lee","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176882_bib91","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1159\/000495897","article-title":"Type I interferons: distinct biological activities and current applications for viral infection","volume":"51","author":"Li","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ejphar.2024.176882_bib92","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1089\/jir.1995.15.55","article-title":"Human type I interferon receptor, IFNAR, is a heavily glycosylated 120-130 kD membrane protein","volume":"15","author":"Ling","year":"1995","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.ejphar.2024.176882_bib93","doi-asserted-by":"crossref","first-page":"6001","DOI":"10.1073\/pnas.0601523103","article-title":"Viral and therapeutic control of IFN-\u03b2 promoter stimulator 1 during hepatitis C virus infection","volume":"103","author":"Loo","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejphar.2024.176882_bib94","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3390\/pathogens9120989","article-title":"The key roles of interferon lambda in human molecular defense against respiratory viral infections","volume":"9","author":"Lozhkov","year":"2020","journal-title":"Pathogens"},{"key":"10.1016\/j.ejphar.2024.176882_bib95","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nn.3367","article-title":"Identification of NUB1 as a suppressor of mutant Huntingtin toxicity via enhanced protein clearance","volume":"16","author":"Lu","year":"2013","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176882_bib96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0635-8","article-title":"Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes","volume":"7","author":"Lu","year":"2019","journal-title":"Journal for immunotherapy of cancer"},{"key":"10.1016\/j.ejphar.2024.176882_bib97","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/glia.23028","article-title":"Type\u20101 interferons contribute to the neuroinflammatory response and disease progression of the MPTP mouse model of Parkinson's disease","volume":"64","author":"Main","year":"2016","journal-title":"Glia"},{"key":"10.1016\/j.ejphar.2024.176882_bib98","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.neuroscience.2018.07.007","article-title":"Optineurin insufficiency disbalances proinflammatory and anti-inflammatory factors by reducing microglial IFN-\u03b2 responses","volume":"388","author":"Markovinovic","year":"2018","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2024.176882_bib99","doi-asserted-by":"crossref","first-page":"9839","DOI":"10.1523\/JNEUROSCI.2496-09.2009","article-title":"Systemic lipopolysaccharide protects the brain from ischemic injury by reprogramming the response of the brain to stroke: a critical role for IRF3","volume":"29","author":"Marsh","year":"2009","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176882_bib100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.606456","article-title":"Type I interferon (IFN)-regulated activation of canonical and non-canonical signaling pathways","volume":"11","author":"Mazewski","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176882_bib101","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2024.176882_bib102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-019-1417-4","article-title":"Anti-inflammatory and cognitive effects of interferon-\u03b21a (IFN\u03b21a) in a rat model of Alzheimer's disease","volume":"16","author":"Mud\u00f2","year":"2019","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ejphar.2024.176882_bib103","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1126\/science.8009221","article-title":"Functional role of type I and type II interferons in antiviral defense","volume":"264","author":"M\u00fcller","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2024.176882_bib104","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1468-1331.1998.520187.x","article-title":"Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta\u20101a after intramuscular and subcutaneous administration","volume":"5","author":"Munafo","year":"1998","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejphar.2024.176882_bib105","doi-asserted-by":"crossref","DOI":"10.1615\/CritRevImmunol.v31.i6.20","article-title":"Induction and function of IFN\u03b2 during viral and bacterial infection","volume":"31","author":"Nagarajan","year":"2011","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2024.176882_bib106","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1089\/jir.2014.0021","article-title":"Interferons, signal transduction pathways, and the central nervous system","volume":"34","author":"Nallar","year":"2014","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.ejphar.2024.176882_bib107","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41578-021-00394-w","article-title":"Drug delivery to the central nervous system","volume":"7","author":"Nance","year":"2022","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.ejphar.2024.176882_bib108","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1084\/jem.157.3.1020","article-title":"Human immune interferon gene is located on chromosome 12","volume":"157","author":"Naylor","year":"1983","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ejphar.2024.176882_bib109","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.3727\/096368912X657882","article-title":"Interferon-\u03b2 delivery via human neural stem cell abates glial scar formation in spinal cord injury","volume":"22","author":"Nishimura","year":"2013","journal-title":"Cell Transplant."},{"key":"10.1016\/j.ejphar.2024.176882_bib110","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.3390\/biomedicines11123331","article-title":"Rodent models of huntington's disease: an overview","volume":"11","author":"Nittari","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejphar.2024.176882_bib111","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nm1425","article-title":"Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury","volume":"12","author":"Okada","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2024.176882_bib112","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/glia.22608","article-title":"Interferons in the central nervous system: a few instruments play many tunes","volume":"62","author":"Owens","year":"2014","journal-title":"Glia"},{"key":"10.1016\/j.ejphar.2024.176882_bib113","first-page":"369","article-title":"Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis","author":"Paolicelli","year":"2009","journal-title":"Biol. Targets & Ther."},{"key":"10.1016\/j.ejphar.2024.176882_bib114","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.3390\/pharmaceutics15102473","article-title":"Uptake transporters at the blood\u2013brain barrier and their role in brain drug disposition","volume":"15","author":"Parvez","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejphar.2024.176882_bib115","doi-asserted-by":"crossref","first-page":"20047","DOI":"10.1074\/jbc.R700004200","article-title":"The interferons: 50 years after their discovery, there is much more to learn","volume":"282","author":"Pestka","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2024.176882_bib116","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/imr.12001","article-title":"Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation","volume":"250","author":"Piehler","year":"2012","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ejphar.2024.176882_bib117","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.3390\/ijms22094405","article-title":"Neuroinflammation in post-ischemic neurodegeneration of the brain: friend, foe, or both?","volume":"22","author":"Pluta","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.176882_bib118","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.rinim.2015.10.001","article-title":"Expression and regulation of Schlafen (SLFN) family members in primary human monocytes, monocyte-derived dendritic cells and T cells","volume":"5","author":"Puck","year":"2015","journal-title":"Results in immunology"},{"key":"10.1016\/j.ejphar.2024.176882_bib119","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.621645","article-title":"Are we ready for cell therapy to treat stroke?","volume":"9","author":"Rasc\u00f3n-Ram\u00edrez","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejphar.2024.176882_bib120","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.3389\/fimmu.2020.01030","article-title":"Regulation of MAVS expression and signaling function in the antiviral innate immune response","volume":"11","author":"Ren","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176882_bib121","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/PL00005780","article-title":"Interferon modulates glucose-sensitive neurons in the hypothalamus","volume":"116","author":"Reyes-Vazquez","year":"1997","journal-title":"Exp. Brain Res."},{"key":"10.1016\/j.ejphar.2024.176882_bib122","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrn2591","article-title":"The bright side of the glial scar in CNS repair","volume":"10","author":"Rolls","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2024.176882_bib123","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jneuroim.2004.02.011","article-title":"Intranasal administration of interferon beta bypasses the blood\u2013brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis","volume":"151","author":"Ross","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.ejphar.2024.176882_bib124","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1074\/jbc.273.14.8003","article-title":"Differences in activity between \u03b1 and \u03b2 type I interferons explored by mutational analysis","volume":"273","author":"Runkel","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2024.176882_bib125","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.2174\/1570159X19666211201094608","article-title":"Neuroinflammation in Huntington's disease: a starring role for astrocyte and microglia","volume":"20","author":"Saba","year":"2022","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ejphar.2024.176882_bib126","doi-asserted-by":"crossref","first-page":"7076","DOI":"10.1038\/sj.onc.1207955","article-title":"Regulated proteolysis of the IFNaR2 subunit of the interferon-alpha receptor","volume":"23","author":"Saleh","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ejphar.2024.176882_bib127","doi-asserted-by":"crossref","unstructured":"Saleiro, D. & Platanias, L.C. (Year) Interferon Signaling in Cancer. Non-canonical Pathways and Control of Intracellular Immune Checkpoints. Vol. 43, Seminars in immunology. Elsevier, City. p. 101299.","DOI":"10.1016\/j.smim.2019.101299"},{"key":"10.1016\/j.ejphar.2024.176882_bib128","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.expneurol.2010.01.009","article-title":"PEGylated interferon-\u03b2 modulates the acute inflammatory response and recovery when combined with forced exercise following cervical spinal contusion injury","volume":"223","author":"Sandrow-Feinberg","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejphar.2024.176882_bib129","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10787-022-00935-x","article-title":"Recombinant human erythropoietin and interferon-\u03b2-1b protect against 3-nitropropionic acid-induced neurotoxicity in rats: possible role of JAK\/STAT signaling pathway","volume":"30","author":"Sayed","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.ejphar.2024.176882_bib130","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3390\/ijms20010190","article-title":"Interferon \u03b2-mediated protective functions of microglia in central nervous system autoimmunity","volume":"20","author":"Scheu","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.176882_bib131","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.0603252","article-title":"Interferon-\u03b3: an overview of signals, mechanisms and functions","volume":"75","author":"Schroder","year":"2004","journal-title":"Journal of Leucocyte Biology"},{"key":"10.1016\/j.ejphar.2024.176882_bib132","doi-asserted-by":"crossref","first-page":"10961","DOI":"10.1021\/acsnano.9b01515","article-title":"Targeting ligands deliver model drug cargo into the central nervous system along autonomic neurons","volume":"13","author":"Sellers","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.ejphar.2024.176882_bib133","article-title":"Neuroprotective effect of acute interferon-beta 1B treatment after spinal cord injury","volume":"23","author":"\u015eeng\u00fcl","year":"2013","journal-title":"Turkish Neurosurgery"},{"key":"10.1016\/j.ejphar.2024.176882_bib134","series-title":"CSF Interferon-\u03b2: A Key Player in Alzheimer's Disease Pathogenesis and Cognitive Impairment","author":"Shen","year":"2023"},{"key":"10.1016\/j.ejphar.2024.176882_bib135","doi-asserted-by":"crossref","first-page":"834","DOI":"10.3390\/v5030834","article-title":"Antiviral type I and type III interferon responses in the central nervous system","volume":"5","author":"Sorgeloos","year":"2013","journal-title":"Viruses"},{"key":"10.1016\/j.ejphar.2024.176882_bib136","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nri3865","article-title":"The multifaceted biology of plasmacytoid dendritic cells","volume":"15","author":"Swiecki","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ejphar.2024.176882_bib137","doi-asserted-by":"crossref","first-page":"4637","DOI":"10.1073\/pnas.1813562116","article-title":"Priming of microglia with IFN-\u03b3 slows neuronal gamma oscillations in situ","volume":"116","author":"Ta","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejphar.2024.176882_bib138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2020.04.060","article-title":"Role of pattern recognition receptors and interferon-beta in protecting bat cell lines from encephalomyocarditis virus and Japanese encephalitis virus infection","volume":"527","author":"Tarigan","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2024.176882_bib139","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.neuroscience.2008.01.013","article-title":"Delivery of interferon-\u03b2 to the monkey nervous system following intranasal administration","volume":"152","author":"Thorne","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2024.176882_bib140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-018-1145-x","article-title":"Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing\u2013remitting multiple sclerosis at year 1","volume":"18","author":"Traboulsee","year":"2018","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ejphar.2024.176882_bib141","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01448","article-title":"Fine-tuning of type I interferon response by STAT3","volume":"10","author":"Tsai","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176882_bib142","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jneuroim.2016.02.012","article-title":"Revelation of the IFN\u03b1, IL-10, IL-8 and IL-1\u03b2 as promising biomarkers reflecting immuno-pathological mechanisms in porcine Huntington's disease model","volume":"293","author":"Valekova","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.ejphar.2024.176882_bib143","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/01.WCB.0000080703.47016.B6","article-title":"Interferon-beta blocks infiltration of inflammatory cells and reduces infarct volume after ischemic stroke in the rat","volume":"23","author":"Veldhuis","year":"2003","journal-title":"J. Cerebr. Blood Flow Metabol."},{"key":"10.1016\/j.ejphar.2024.176882_bib144","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/ni.3212","article-title":"Guarding the frontiers: the biology of type III interferons","volume":"16","author":"Wack","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ejphar.2024.176882_bib145","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrc2694","article-title":"Signal integration by JNK and p38 MAPK pathways in cancer development","volume":"9","author":"Wagner","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejphar.2024.176882_bib146","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.606489","article-title":"The role of structure in the biology of interferon signaling","volume":"11","author":"Walter","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176882_bib147","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00618-19","article-title":"Type I interferon receptor signaling drives selective permissiveness of astrocytes and microglia to measles virus during brain infection","volume":"93","author":"Welsch","year":"2019","journal-title":"J. Virol."},{"key":"10.1016\/j.ejphar.2024.176882_bib148","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.605673","article-title":"Shared and unique features of human interferon-beta and interferon-alpha subtypes","volume":"11","author":"Wittling","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2024.176882_bib149","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1007\/s12035-015-9157-7","article-title":"Therapeutical strategies for spinal cord injury and a promising autologous astrocyte-based therapy using efficient reprogramming techniques","volume":"53","author":"Yang","year":"2016","journal-title":"Mol. Neurobiol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924005715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924005715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T16:14:47Z","timestamp":1729872887000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299924005715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":149,"alternative-id":["S0014299924005715"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.176882","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of interferon beta in neurological diseases and its potential therapeutic relevance","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.176882","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"176882"}}